Logo of Nexsen (ASX:NXN)Latest Nexsen (ASX:NXN) News

Page 1
Page 1 of 3

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Nexsen clears quality hurdle as StrepSure moves towards FDA submission

Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
2 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Nexsen broadens GBS strategy as StrepSure FDA submission moves to early 2027

Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
28 Oct 2026

Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.
Logan Eniac
26 Sept 2026

Nexsen proposes 50:50 FlashDx venture to accelerate molecular GBS testing

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.
Victor Sage
25 Sept 2026

Nexsen suspends shares as StrepSure FDA submission slips and device contract looms

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.
Ada Torres
24 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Nexsen posts $6.55m loss in FY26 as clinical trials and Asia-Pacific expansion gain momentum

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 26 (22 June -> 26 June) 2026

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.
Logan Eniac
27 June 2026

Nexsen Secures $1.5M Non-Dilutive Funding to Boost Diagnostics Manufacturing

Nexsen has locked in over $1.5 million in non-dilutive funding through a national research partnership, accelerating manufacturing scale-up and platform optimisation for its rapid diagnostics technology.
Ada Torres
25 June 2026

Market Wrap - Week 20 (11 May -> 15 May) 2026

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.
Logan Eniac
16 May 2026